Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1971 1
1973 1
1977 2
1978 1
1980 1
1981 1
1983 1
1986 1
1988 1
1989 1
1990 5
1991 2
1992 2
1995 3
1996 2
1997 2
1998 1
1999 3
2000 4
2001 1
2002 2
2003 4
2004 2
2005 8
2006 8
2007 5
2008 6
2009 9
2010 8
2011 9
2012 5
2013 4
2014 5
2015 2
2016 1
2017 2
2018 1
2019 1
2020 1
2021 1
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L; Gruppo Italiano Mammella Investigators. Del Mastro L, et al. Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10. Lancet Oncol. 2022. PMID: 36370716 Clinical Trial.
Progress in the treatment of gastrointestinal cancer.
Massidda B, Rougier P. Massidda B, et al. Ann Oncol. 2003;14 Suppl 2:ii1-2. doi: 10.1093/annonc/mdg721. Ann Oncol. 2003. PMID: 12810449 Free article. Review. No abstract available.
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Palmeri S, Vaglica M, Spada S, Filippelli G, Farris A, Palmeri L, Massidda B, Misino A, Ferraù F, Comella G, Leonardi V, Condemi G, Mangiameli A, De Cataldis G, Macaluso MC, Cajozzo M, Iannitto E, Danova M. Palmeri S, et al. Among authors: massidda b. Oncology. 2005;68(4-6):438-45. doi: 10.1159/000086986. Epub 2005 Jul 14. Oncology. 2005. PMID: 16020974 Free article. Review.
Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer.
Formica V, Ionta MT, Massidda B, Vessia G, Maiorino L, Casaretti R, Natale D, Barberis G, Filippelli G, Greco E, Blasi L, Mancarella S, Russo A, Barbato E, Lullo LD, Roselli M. Formica V, et al. Among authors: massidda b. Oncotarget. 2017 Dec 17;9(2):2876-2886. doi: 10.18632/oncotarget.23355. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416820 Free PMC article.
Cholesterol esters as growth regulators of lymphocytic leukaemia cells.
Mulas MF, Abete C, Pulisci D, Pani A, Massidda B, Dessì S, Mandas A. Mulas MF, et al. Among authors: massidda b. Cell Prolif. 2011 Aug;44(4):360-71. doi: 10.1111/j.1365-2184.2011.00758.x. Epub 2011 Jun 6. Cell Prolif. 2011. PMID: 21645151 Free PMC article.
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Colucci G, et al. Among authors: massidda b. J Clin Oncol. 2010 Apr 1;28(10):1645-51. doi: 10.1200/JCO.2009.25.4433. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194854 Clinical Trial.
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, Banzi M, Zaniboni A, Pasini F, Bozzarelli S, Garattini SK, Ferrari D, Montesarchio V, Mambrini A, Ciuffreda L, Galli F, Pusceddu V, Carlomagno C, Bidoli P, Amoroso D, Bochicchio AM, Frassineti L, Corsi D, Bilancia D, Pastorino A, De Stefano A, Labianca R; TOSCA (Three or Six Colon Adjuvant) investigators. Rosati G, et al. Eur J Cancer. 2021 May;148:190-201. doi: 10.1016/j.ejca.2021.01.051. Epub 2021 Mar 18. Eur J Cancer. 2021. PMID: 33744715
Stop Flow in abdominal and pelvic cancer relapses.
Iaffaioli RV, Facchini G, Tortoriello A, Crovella F, Romano G, Formato R, Santangelo M, Barletta E, Fiore F, Iaccarino V, Memoli B, D'Angelo R, Pilati PL, Rossi R, Guadagni S, Deraco M, Pignata S, Daniele B, Rosati G, Massidda B, Mantovani G, Di Salvo E, Marzano N, Memeo V, Parisi V, Mallarini G, Colucci G. Iaffaioli RV, et al. Among authors: massidda b. Front Biosci. 2006 May 1;11:1284-8. doi: 10.2741/1882. Front Biosci. 2006. PMID: 16368515 Clinical Trial.
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.
Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P; “FOLLOW-UP” Study Group. Natoli C, et al. PLoS One. 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014. PLoS One. 2014. PMID: 24714591 Free PMC article.
114 results